Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said ...
New research shows GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...
Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...
Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...
OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...
Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback